Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 5 trials

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

3Total
Not Applicable (2)
P 3 (1)

Trial Status

Recruiting3
Enrolling By Invitation1
Not Yet Recruiting1

Clinical Trials (5)

Showing 5 of 5 trials
NCT07587242Phase 3Recruiting

A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping

NCT07127978RecruitingPrimary

A Study Evaluating the Real-World Experience of Givinostat in Patients With Duchenne Muscular Dystrophy

NCT07378553RecruitingPrimary

Multiparametric Ultrafast Ultrasound Biomarkers for Duchenne and Becker Muscular Dystrophies

NCT07629284Not ApplicableEnrolling By InvitationPrimary

Home-Based Tele-Rehabilitation for Respiratory Function in Children With Duchenne Muscular Dystrophy

NCT07581743Not ApplicableNot Yet RecruitingPrimary

How Can Different Forms of Strengthening Exercises Affect the Muscular Tissue and Its Chemical Markers in Children With Duchenne Muscular Dystrophy

Showing all 5 trials

Research Network

Activity Timeline